Ardelyx (ARDX) Stock Rating Lowered by BidaskClub

Ardelyx (NASDAQ:ARDX) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a report released on Friday.

A number of other analysts also recently issued reports on ARDX. Cantor Fitzgerald set a $12.00 target price on Ardelyx and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Citigroup raised their target price on Ardelyx from $14.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, October 12th. Leerink Swann reissued an “outperform” rating and issued a $13.00 target price on shares of Ardelyx in a research report on Tuesday, October 17th. Zacks Investment Research downgraded Ardelyx from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Finally, Ladenburg Thalmann Financial Services decreased their target price on Ardelyx from $19.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, November 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. Ardelyx currently has an average rating of “Buy” and a consensus price target of $12.64.

Shares of Ardelyx (NASDAQ:ARDX) traded up $0.20 on Friday, hitting $7.30. The company had a trading volume of 275,564 shares, compared to its average volume of 288,197. The stock has a market capitalization of $346.35, a P/E ratio of -3.27 and a beta of 0.35. Ardelyx has a one year low of $4.05 and a one year high of $15.40.

Ardelyx (NASDAQ:ARDX) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.10. During the same period in the previous year, the company earned ($0.65) earnings per share. equities analysts forecast that Ardelyx will post -2.01 EPS for the current fiscal year.

In other news, COO Reginald Seeto sold 10,008 shares of the firm’s stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $5.20, for a total value of $52,041.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 15.47% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. Tudor Investment Corp ET AL bought a new position in shares of Ardelyx in the second quarter worth $111,000. Parametric Portfolio Associates LLC boosted its holdings in shares of Ardelyx by 8.9% in the second quarter. Parametric Portfolio Associates LLC now owns 27,581 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 2,252 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Ardelyx by 18.5% in the second quarter. The Manufacturers Life Insurance Company now owns 31,252 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 4,871 shares during the period. Rhumbline Advisers boosted its holdings in shares of Ardelyx by 15.6% in the second quarter. Rhumbline Advisers now owns 40,516 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 5,465 shares during the period. Finally, Citadel Advisors LLC bought a new position in shares of Ardelyx in the second quarter worth $248,000. 76.12% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Ardelyx (ARDX) Stock Rating Lowered by BidaskClub” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/21/ardelyx-ardx-stock-rating-lowered-by-bidaskclub.html.

Ardelyx Company Profile

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Analyst Recommendations for Ardelyx (NASDAQ:ARDX)

Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply